LYPD1 and breast carcinoma: Shi et al. (2016) observed that HULC can act as an oncogene biomarker in triple-negative breast cancer and as an independent possible poor prognostic factor in patients suffered from triple-negative breast cancer. Wang et al. (2019) found that HULC can promote the development of breast cancer through regulating the expression of LYPD1. Gavgani et al. (2020) investigated that the HULC knockdown can induce apoptosis and suppress cellular migration in breast cancer cells.